Literature DB >> 25236941

Culprit vessel only vs immediate complete revascularization in patients with acute ST-segment elevation myocardial infarction: systematic review and meta-analysis.

Nigar Sekercioglu1, Frederick A Spencer, Luciane Cruz Lopes, Gordon H Guyatt.   

Abstract

Although multivessel coronary artery disease has been associated with poor health outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI), the optimal approach to revascularization remains uncertain. The objective of this review was to determine the benefits and harms of culprit vessel only vs immediate complete percutaneous coronary intervention (PCI) in patients with acute STEMI. We searched MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) for randomized controlled trials (RCTs). Teams of 2 reviewers, independently and in duplicate, screened titles and abstracts, completed full-text reviews, and abstracted data. We calculated pooled risk ratios (RRs) and associated 95% confidence intervals (CIs) using random-effect models for nonfatal myocardial infarction (MI), revascularization, cardiovascular mortality, all-cause mortality, and adverse events, and used the GRADE approach to rate confidence in estimates of effect. Of 341 patients randomized to complete revascularization and followed to study conclusion, 31 experienced revascularization, as did 80 of 324 randomized to culprit vessel only revascularization (RR: 0.35, 95% CI: 0.24-0.53). Ten patients in the complete revascularization group and 28 patients in the culprit vessel only revascularization group experienced nonfatal MI (RR: 0.35, 95% CI: 0.17-0.72). All-cause mortality and cardiac deaths did not differ between groups (RR: 0.69, 95% CI: 0.40-1.21 for all-cause mortality; RR: 0.48, 95% CI: 0.22-1.04 for cardiac deaths). Pooled data from 3 RCTs suggest that immediate complete revascularization probably reduces revascularization in patients with acute STEMI; although results suggest possible benefits on MI and death, confidence in estimates is low.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25236941      PMCID: PMC6647587          DOI: 10.1002/clc.22333

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

Review 1.  Reperfusion strategies in acute myocardial infarction and multivessel disease.

Authors:  Birgit Vogel; Shamir R Mehta; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2017-06-29       Impact factor: 32.419

Review 2.  Revascularization Strategies in STEMI with Multivessel Disease: Deciding on Culprit Versus Complete-Ad Hoc or Staged.

Authors:  Shalin Patel; Steven R Bailey
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 3.  Optimal Timing of Complete Revascularization in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Rouan Gaffar; Bettina Habib; Kristian B Filion; Pauline Reynier; Mark J Eisenberg
Journal:  J Am Heart Assoc       Date:  2017-04-10       Impact factor: 5.501

4.  Complete Treatment Versus Residual Lesion - Long-Term Evolution After Acute Coronary Syndrome.

Authors:  Alexandre de Matos Soeiro; Marco Antônio Scanavini Filho; Aline Siqueira Bossa; Cindel Nogueira Zullino; Maria Carolina F Almeida Soeiro; Tatiana Carvalho Andreucci T Leal; Carlos Vicente Serrano; Ludhmila Abrahão Hajjar; Roberto Kalil Filho; Múcio Tavares Oliveira
Journal:  Arq Bras Cardiol       Date:  2016-12       Impact factor: 2.000

Review 5.  Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Vinayak Nagaraja; Sze-Yuan Ooi; James Nolan; Adrian Large; Mark De Belder; Peter Ludman; Rodrigo Bagur; Nick Curzen; Takashi Matsukage; Fuminobu Yoshimachi; Chun Shing Kwok; Colin Berry; Mamas A Mamas
Journal:  J Am Heart Assoc       Date:  2016-12-16       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.